Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria

BACKGROUND: Chimeric antigen receptor T-cell therapy (CART) prolongs survival for patients with refractory or relapsed lymphoma. Discrepancies among different response criteria for lymphoma under CART were recently shown. Our objective was to evaluate reasons for discordance among different response...

Descripción completa

Detalles Bibliográficos
Autores principales: Winkelmann, Michael, Blumenberg, Viktoria, Rejeski, Kai, Bücklein, Veit L., Ingenerf, Maria, Unterrainer, Marcus, Schmidt, Christian, Dekorsy, Franziska J., Bartenstein, Peter, Ricke, Jens, von Bergwelt-Baildon, Michael, Subklewe, Marion, Kunz, Wolfgang G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184388/
https://www.ncbi.nlm.nih.gov/pubmed/37189191
http://dx.doi.org/10.1186/s40644-023-00566-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184388/
https://www.ncbi.nlm.nih.gov/pubmed/37189191
http://dx.doi.org/10.1186/s40644-023-00566-7

Ejemplares similares